A phase II, randomized, parallel group, placebo-controlled, double-blinded, dose-finding study to evaluate efficacy, safety, tolerability, and pharmacokinetics of ABY-035 in subjects with moderate-to-severe plaque psoriasis
Phase of Trial: Phase I/II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs ABY 035 (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Therapeutic Use
- Acronyms AFFIRM-35 Study
- Sponsors Affibody
- 06 Sep 2017 According to an Affibody media release, interim data from this trial will be presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress.
- 24 May 2017 New trial record
- 10 May 2017 According to an Affibody media release, the first part of the study included 46 healthy volunteers that were treated with escalating doses of ABY-035.